InvestorsHub Logo
Followers 9
Posts 836
Boards Moderated 0
Alias Born 06/24/2014

Re: l2 hunter post# 1008

Wednesday, 07/25/2018 8:31:59 PM

Wednesday, July 25, 2018 8:31:59 PM

Post# of 1689
This is just one reason for all the catalysts this company has under its belt.

As part of the Sublicense Agreement, Baxalta agreed to pay Xenetic a one-time payment of $7.5 million and single digit royalty payments based upon net sales of the products covered under the sublicense throughout the term of the agreement.

Xenetic has previously received strategic investments from OPKO Health (Nasdaq:OPK), Serum Institute of India Limited and PJSC Pharmsynthez.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent XBIO News